DDInter898 DDInter1628
Indium or yttrium conjugated murine IgG1 kappa monoclonal antibody directed against the CD20 antigen, which is found on the surface of normal and malignant B lymphocytes. Ibritumomab is produced in Chinese hamster ovary cells and is composed of two murine gamma 1 heavy chains of 445 amino acids each and two kappa light chains of 213 amino acids each.
Ruxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. It is a potent and selective inhibitor of JAK1 and JAK2, which are tyrosine kinases involved in cytokine signalling and hematopoiesis. Myeloproliferative neoplasms, such as myelofibrosis and polycythemia vera, are often characterized by aberrant activation of the JAK-STAT pathway, leading to abnormal blood cell counts and thrombotic complications. By inhibiting JAK1 and JAK2, ruxolitinib works to block the dysregulated cell signalling pathways and prevents abnormal blood cell proliferation. Due to a large number of patients with myeloproliferative neoplasms who have JAK2 mutations, ruxolitinib was the first ATP-competitive inhibitor of JAK1 and JAK2 ever developed. Ruxolitinib was first approved for the treatment of adult patients with myelofibrosis by the FDA in 2011, followed by EMA's approval in 2012. In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in steroid-refractory acute graft-versus-host disease in adults and children. The topical formulation of ruxolitinib is used to treat atopic dermatitis and vitiligo. It is being investigated for other inflammatory skin conditions. Ruxolitinib has been investigated to treat patients with coronavirus disease 2019 (COVID-19) accompanied by severe systemic hyperinflammation. In phase II clinical trials, ruxolitinib improved chest computed tomography and improved recovery in patients with lymphopenia.[A229713, A229718] However, phase III clinical trials later determined that ruxolitinib was inadequate in meeting its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe complications thus the drug was not approved as a treatment for COVID-19.
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ticagrelor {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ticagrelor
Ticagrelor {u} (Compound) causes {v} (Side Effect) Fatigue
Fatigue {u} (Side Effect) is caused by {v} (Compound) Ruxolitinib
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Duloxetine
Duloxetine {u} (Compound) downregulates {v} (Gene) PIN1
PIN1 {u} (Gene) is downregulated by {v} (Compound) Ruxolitinib
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) downregulates {v} (Gene) PLK4
PLK4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Topotecan
Topotecan {u} (Compound) downregulates {v} (Gene) FOXJ3
FOXJ3 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Fluoxetine {u} (Compound) upregulates {v} (Gene) HMGCR
HMGCR {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Chloramphenicol {u} (Compound) upregulates {v} (Gene) PHKG2
PHKG2 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ibritumomab tiuxetan {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nepafenac
Nepafenac {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Meclofenamic acid
Meclofenamic acid {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Ruxolitinib
Ibritumomab tiuxetan {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Clozapine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Ruxolitinib
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ruxolitinib (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine (Compound) downregulates PIN1 (Gene) and PIN1 (Gene) is downregulated by Ruxolitinib (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) downregulates PLK4 (Gene) and PLK4 (Gene) is bound by Ruxolitinib (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) downregulates FOXJ3 (Gene) and FOXJ3 (Gene) is upregulated by Ruxolitinib (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) upregulates HMGCR (Gene) and HMGCR (Gene) is upregulated by Ruxolitinib (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol (Compound) upregulates PHKG2 (Gene) and PHKG2 (Gene) is bound by Ruxolitinib (Compound)
Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac and Nepafenac (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Meclofenamic acid and Meclofenamic acid (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Ruxolitinib (Compound)
Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ruxolitinib (Compound)